Uni-Bio Science Group Limited (HKG:0690)
Hong Kong · Delayed Price · Currency is HKD 0.0600
-0.0020 (-3.23%)
Aug 27, 2026, 4:08 PM HKT
Uni-Bio Science Group Revenue
Uni-Bio Science Group had revenue of 275.99M HKD in the half year ending December 31, 2025, with 17.55% growth. This brings the company's revenue in the last twelve months to 549.77M, down -6.75% year-over-year. In the year 2025, Uni-Bio Science Group had annual revenue of 586.21M with 6.01% growth.
Revenue (ttm)
549.77M
Revenue Growth
-6.75%
P/S Ratio
0.65
Revenue / Employee
1.01M
Employees
543
Market Cap
358.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 586.21M | 33.23M | 6.01% |
| Dec 31, 2024 | 552.98M | 68.26M | 14.08% |
| Dec 31, 2023 | 484.72M | 44.40M | 10.08% |
| Dec 31, 2022 | 440.32M | 86.91M | 24.59% |
| Dec 31, 2021 | 353.41M | 144.63M | 69.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3D Medicines | 396.26M |
| Cutia Therapeutics | 374.07M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 74.40M |
| Brii Biosciences | 66.16M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Kintor Pharmaceutical | 36.37M |
| Transcenta Holding | 8.27M |
Uni-Bio Science Group News
- 1 year ago - Uni-Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches : Pioneering Entry into the High-Growth Medical Aesthetics Market - Zawya